A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The maximum tolerated dose of vorinostat with concurrent radiosurgery will be determined.
30 days following Stereotactic Radiosurgery
Griffith R. Harsh
United States: Institutional Review Board
|Stanford University School of Medicine||Stanford, California 94305-5317|
|Moffitt Cancer Center||Tampa, Florida 33612|